Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 2011

View Archived Issues

Novel protein kinase inhibitors reported

PANORAMA 1 study evaluates panobinostat in multiple myeloma

Phase III trial assesses olesoxime plus riluzole in ALS

PARP inhibitor shows promise combined with temozolomide in advanced solid tumors

GeoVax Labs vaccinates first patient in phase I/II AIDS trial

Liquidia Technologies and PATH to collaborate

Catalyst Pharmaceutical moves CPP-115 into clinic

NKTR-181 trial yields promising results

BioLineRx to develop novel peptide drugs discovered by Compugen

Camurus grants Novartis exclusive licensing options

Threshold reports encouraging results from ongoing TH-302 trial in advanced leukemias

GSK files for Japanese approval of oral kinase inhibitor in malignant soft tissue sarcoma

New schistosomiasis vaccine candidate developed in Switzerland

New malaria vaccines tested in vivo by U.S. investigators

AVL-292 may alleviate myeloma-related bone disease

Phase II data encourage further development of aminopeptidase N inhibitor in leukemia

Salix Pharmaceuticals files NDA for crofelemer

Metabolic Pharmaceuticals begins investigating AOD-9604 in two new areas

Onyx Pharmaceuticals joins MMRF's personalized medicine initiative

New conjugated antisense oligonucleotides prepared in U.S.

Novel histamine H3 receptor antagonists/inverse agonists disclosed

Chinese institute patents novel serotonin modulators

Kyowa Hakko Kirin presents novel kynurenine production inhibitors

Wilex discusses development of Redectane with FDA

Catabasis raises additional funding for CAT-2003 development in hypertriglyceridemia

Dako's HER2 CISH pharmDx kit approved in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Fauci’s silence may put him in contempt of Congress
BioWorld
After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...